Relatient Launches Dash Voice AI Agent to Automate Patient Appointment Management in Call Centers
ATLANTA--(BUSINESS WIRE)-- Relatient, the leading patient scheduling platform, today announced the launch of Dash Voice AI, an advanced conversational AI feature of its Dash Schedule solution. The Dash Voice AI agent revolutionizes patient appointment management by automating the handling of high-volume appointment-related phone calls, including confirmations, rescheduling and cancellations, while leveraging the Dash platform's existing rules-based intelligence. This ensures every interaction follows provider-specific preferences in real-time.
'When patients call a practice, Dash Voice AI integrates seamlessly into our client's phone sytem to deliver a remarkably natural conversational experience, making interactions feel personal and high touch,' said Jeff Gartland, CEO of Relatient.
Share
Healthcare contact centers face growing pressure from rising patient call volumes and consumer expectations. Despite these demands, scheduling an appointment by phone can take as long as 8 minutes of staff time. Dash Voice AI reduces that burden by managing scheduling-related calls 24/7, without the need for more agents. The result: shorter hold times for patients and more time for staff to focus on high-touch and high-value tasks.
Core capabilities and measurable impact of Dash Voice AI include:
Orchestrated Intelligence: A coordinated, rules-based engine that adapts in real time to provider-specific preferences, managing scheduling decisions automatically, without manual intervention.
Human-Like Conversation: Delivers natural, low-latency interactions, while preventing hallucinations by grounding responses in the Dash platform's scheduling logic.
Simultaneous Call Handling: Manages hundreds of calls at once, helping reduce wait times and improve efficiency.
25% Call Deflection: Offloads, on average, a quarter of scheduling related call volume instantly, boosting speed and lightening staff load.
Maximize Capacity: Frees skilled human representatives to focus on high-impact work, while promptly handling routine inquiries with a personable, cost-optimized solution.
'When patients call a practice, Dash Voice AI integrates seamlessly into our client's phone sytem to deliver a remarkably natural conversational experience, making interactions feel personal and high touch,' said Jeff Gartland, CEO of Relatient. 'Beyond the patient experience, the true innovation lies in how Dash Voice AI leverages the intelligence in the core Dash platform, enhancing the contact center experience while delivering substantial capacity relief by fully automating routine tasks. Organizations now have a scalable solution that maximizes staff resources while consistently ensuring accurate, patient-centric scheduling.'
Early adopters are already recognizing the significant impact of Dash Voice AI.
'At Raleigh Orthopaedic, we anticipate Dash Voice AI will dramatically enhance our capacity to serve patients without additional staffing,' said Ross Rigdon, COO of Raleigh Orthopaedic. 'This AI solution will enable us to efficiently handle high volumes of scheduling calls, maintaining the quality, speed and personal touch our patients expect. It will be integral to our patient access and operational strategies.'
Healthcare contact centers continue to experience high call abandonment rates and long hold times, juggling a myriad of inquiries from appointment management to care team questions. Dash Voice AI can extend across these different tasks, including scheduling new appointments, providing directions to the facility, sharing instructions and more.
'Beginning with the strong foundation of an intelligent scheduling platform means the opportunities with this tool are limitless,' Gartland said. 'We're excited to be on this journey with our clients and with their help, will continue to expand Dash Voice AI's use cases and impact.'
About Relatient, Inc.
Relatient, Inc., is the premier provider of intelligent patient scheduling and engagement technology, leveraging a data-led approach to enhance access to care. Each year, the platform engages with over 50 million unique patients on behalf of provider groups and health systems nationwide. These solutions drive operational efficiency, increase appointments, reduce no-shows, expedite patient payments, and boost patient satisfaction, all while supporting better health and care quality initiatives. For more information, visit: http://www.relatient.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
VideoAmp Launches THE REPLAY Revealing New Insights Into Live Sports Audiences
NEW YORK, June 13, 2025--(BUSINESS WIRE)--Today, VideoAmp is debuting a new monthly insights report called THE REPLAY – an interactive analysis of television viewership across major sports tentpole events. Each edition of THE REPLAY will explore the nuances of viewing behavior, regional loyalty, and audience segmentation that shape how America tunes in at home and in public venues leveraging VideoAmp's out-of-home measurement tools. VideoAmp's out-of-home measurement examines whether fans gathered in public venues or stayed home for the big game. Powered by VideoAmp's VALID™ big data and tech engine, THE REPLAY delivers advanced audience ratings and household-level insights in a highly visual and interactive public-facing tool. "For media companies and advertisers alike, THE REPLAY will become a must-use tool for decision-making," said Peter Liguori, Executive Chairman of VideoAmp. "This isn't simply a monthly data dump. Our experts and analysts will be providing an unprecedented and thoughtful look at sports media consumption, and the unique moments when brands can reach passionate, highly engaged viewers that only VideoAmp's advanced audience capabilities make possible." The first edition of THE REPLAY looks back on this year's March Madness, examining how fans watched and where their loyalties shifted. From out-of-home spikes to changing regional dynamics, behavior evolved each round. For example, this month's edition found that during the later rounds of the tournament, the audience included a higher share of top investor households (having at least $100K in invested assets) and those with high discretionary income (HHs $200K). The March 30th Michigan v Auburn game and all the Final Four games including the Championship saw over 1m+ $200k households tune in. The next edition, coming in early July, will highlight the NBA Finals with future months set to explore The Stanley Cup Finals, the NFL season opener and the US Open. In 2024, 75 of the top 100 programs in terms of live audience were sports programming. Streamers know this, and are increasingly investing more in the space. Emarketer recently published a report that projected that over 105 million U.S. viewers watched live sports digitally in 2024, an increase from 95.5 million during the previous year. That same report expects digital viewing of live sports will reach 127.4 million viewers in the U.S., a 21% increase from 2024. About VideoAmp VideoAmp is a media measurement company transforming advertising. By leveraging the power of currency-grade big data, VideoAmp's solutions provide clients with access to advanced audiences and the ability to precisely plan, optimize and measure media investments across platforms to achieve better outcomes. With these solutions, media sellers can increase the value of their inventory, while advertisers can benefit from increased return on investment. VideoAmp has seen incredible adoption for its measurement and currency solutions with 880% YoY growth, 98% coverage of the TV publisher ecosystem, 11 agency groups and more than 1,000+ advertisers. VideoAmp is headquartered in Los Angeles and New York with offices across the United States. To learn more, visit View source version on Contacts Media Contact:Cassady NordeenCassady@ Sign in to access your portfolio
Yahoo
18 minutes ago
- Yahoo
CORRECTING and REPLACING Smart Meter Selected By 9amHealth for Major Employer Weight Management Programs Using Cellular Weight Scale
TAMPA, Fla., June 13, 2025--(BUSINESS WIRE)--Please replace the release dated June 11, 2025 with the following corrected version due to multiple revisions. The updated release reads: SMART METER SELECTED BY 9AMHEALTH FOR MAJOR EMPLOYER WEIGHT MANAGEMENT PROGRAMS USING CELLULAR WEIGHT SCALE Smart Meter, a pioneer in cellular-enabled weight scale technology, today announced a strategic supply agreement with 9amHealth, a leading provider of comprehensive weight management and cardiometabolic benefits for large employers. This collaboration integrates Smart Meter's advanced cellular weight scales into 9amHealth's multi-disciplinary care platform, delivering real-time health data and enhanced outcomes for employees at major technology companies and Fortune 500 organizations. Addressing Critical Gaps in Employee Weight Management for Millions of Americans The partnership addresses a significant challenge identified by leading employers: while lifestyle changes remain the foundation of managing weight, traditional approaches often lack the consistent monitoring and data integration required to achieve and maintain goals. With major tech companies already deploying 9amHealth's solution, the addition of Smart Meter's cellular scales provides seamless, automatic data collection that eliminates barriers to consistent tracking. "We're seeing tremendous demand from large employers who want to move beyond BMI-only assessments and provide their employees with easy-to-use technology to support better weight management," said Casey Pittock, CEO at Smart Meter. "Our cellular scales integrate perfectly with 9amHealth's clinical approach, providing real-time data that allows physicians, pharmacists, and dietitians to deliver personalized care." Enhancing Clinical Care with Real-Time Data 9amHealth's evidence-based program combines physicians, pharmacists, and registered dietitians trained in obesity care, available virtually across all 50 states. The integration of Smart Meter's cellular scales enhances this care model by: Automatic Data Transmission: Eliminating the need for manual weight logging, reducing friction in the patient experience Real-Time Clinical Insights: Enabling care teams to monitor progress and adjust treatment plans promptly Comprehensive Metabolic Monitoring: Supporting early identification of conditions like prediabetes and diabetes Seamless Integration: Connecting directly with 9amHealth's clinical platform without requiring additional apps or devices "Nearly 10% of new members enrolling in our weight health and cardiometabolic program are found to have previously undiagnosed prediabetes or diabetes," said Dr. Avantika Waring, MD, Chief Medical Officer at 9amHealth. "Smart Meter's cellular scales give us consistent, reliable data that supports early identification of risk patterns and enables more personalized interventions—focused on improving overall health, not just weight loss." Breaking Down Barriers to Participation The device, data, and service agreement specifically addresses socioeconomic challenges that have historically limited participation in employer weight management programs. By removing the complexity of manual tracking and providing technology that works regardless of geographic location, the solution serves remote populations with varying: Cultural preferences around health monitoring Technical comfort levels Geographic limitations Previous experiences with weight management programs Proven Results with Major Technology Companies Leading technology companies have already implemented 9amHealth's comprehensive program, recognizing weight care as an entry point to broader health support for employees with comorbidities. The addition of Smart Meter's cellular scales strengthens these deployments by providing: Consistent engagement through automated tracking Reduced administrative burden on HR teams Enhanced clinical outcomes through better data quality Improved employee satisfaction through simplified user experience Meeting Employees Where They Are Unlike traditional programs that require employees to repeat previous lifestyle interventions before accessing additional care, the 9amHealth solution meets each person where they are in their health journey. Smart Meter's Cellular scales support this philosophy by providing immediate, judgment-free data collection that integrates seamlessly with comprehensive care plans ranging from lifestyle coaching to GLP-1 prescriptions and bariatric surgery referrals when appropriate. About Smart Meter, LLC Smart Meter is the trusted supplier of Remote Patient Monitoring ("RPM") solutions. The company's technology and services empower a nationwide network of SmartPartnersTM who are working directly with healthcare providers to transform patient care. Millions of vital health data readings are reliably delivered across the company's secure platform to enable real-time, better-informed health care. The company's proprietary patient-friendly cellular FDA-registered monitoring devices are connected to an exclusive AT&T 4/5G network to ensure an engaging patient experience for improved adherence. For more information, visit About 9amHealth 9amHealth offers complete cardiometabolic care—a first-of-its-kind, whole-body approach to preventing and treating obesity, diabetes, high cholesterol, and hypertension. They partner with employers, health plans, and PBMs to provide effective health benefits for those living with chronic conditions. Their members receive personalized care plans, prescription delivery, at-home lab tests, and unlimited specialist access. 9amHealth was founded in 2021 by the team behind mySugr and is backed by 7Wire Ventures, Cigna Ventures, Human Capital, Founders Fund, and Define Ventures. Learn more at View source version on Contacts Media Contact Keith 336-509-8024 Sign in to access your portfolio
Business Wire
31 minutes ago
- Business Wire
Valar Labs' CHAI Biomarkers Validated in New Study in European Urology for Predicting Outcomes of High Grade Ta Bladder Cancer
PALO ALTO, Calif.--(BUSINESS WIRE)--Valar Labs, a pioneer in AI-powered diagnostics for oncology, announced the publication of its latest research in European Urology, the highest-impact journal in the field of urology. The peer-reviewed study highlights the performance and clinical impact of Valar Labs' Vesta platform in prognosticating outcomes for patients with high grade Ta non muscle invasive bladder cancer, a population frequently on the borderline of guideline-based risk stratification who may receive different treatment depending on which guideline their provider uses. This study demonstrated that CHAI biomarkers can offer improved and additional risk stratification that can go beyond traditional risk factors to better prognosticate outcomes in this population - Dr. Sam S. Chang Bladder cancer treatment remains highly variable in its outcomes, with limited tools available to tailor therapies to individual patients. Valar Labs' Vesta platform, built using advanced artificial intelligence, analyzes pathology to provide critical clinical insights. The newly published study demonstrates that Vesta Risk Stratify biomarkers accurately predicts recurrence and disease progression and outperforms existing guideline-based risk stratification, offering a transformative step forward in precision oncology for bladder cancer. Vesta allows for tailored management based on a patient's individual risk. 'HGTa tumors carry differing risks as current guidelines attempt to address, and clinical factors such as tumor focality and size can help delineate the true nature of these tumors. These clinical factors, however, are somewhat crude and can be misleading at times. This study demonstrated that CHAI biomarkers can offer improved and additional risk stratification that can go beyond traditional risk factors to better prognosticate outcomes in this population.' - Dr. Sam S. Chang, Chief Surgical Officer, Vanderbilt Ingram Cancer Center "The ability to derive clinically meaningful predictive and prognostic information from routinely-collected pathology is a paradigm shift for the risk stratification of bladder cancer patients." - Dr. Siamak Daneshmand, Professor of Urology and Medicine (Oncology), and Director of Urologic Oncology, University of Southern California The multi-center validation study was conducted in collaboration with leading academic centers and underscores both the reproducibility and robustness of the CHAI biomarkers. These findings further establish Vesta as a leading precision oncology platform in the management of non-muscle-invasive bladder cancer. 'This publication is a testament to the clinical significance and scientific rigor of our work,' said Anirudh Joshi, CEO of Valar Labs. 'Vesta's prognostic and predictive tests represent a leap forward in precision medicine for bladder cancer—providing physicians and patients with data-driven insights to guide treatment decisions more effectively.' 'This impactful work continues to build on Vesta's evidence base as the leading predictive and prognostic biomarker portfolio in bladder cancer. We are excited for patients and providers to benefit from this technology,' said Viswesh Krishna, CTO of Valar Labs. Valar Labs continues to expand its suite of AI-driven diagnostic tests under the Vesta portfolio and beyond, aiming to improve outcomes across a range of cancers. For more information or to access the full study, please visit About Valar Labs Valar Labs is a precision medicine company developing computational histology AI diagnostic tests for predicting response to cancer therapies. Our mission is to provide every patient and physician the ability to select the best treatment based on the patient's tumor biology. Vesta is our portfolio of diagnostic tests that predicts which patients are unlikely to benefit from BCG therapy and provides detailed risk stratification for recurrence and progression. Vesta BCGPredict and Vesta Risk Stratify HG are clinically available through our CLIA-certified laboratory in Houston, Texas and can be ordered online. For more information, please visit and follow us on LinkedIn and X.
